Wang Zhen, Chen Junqiang, Su Ka, Dong Zhiyong
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuang Yong Road, Nanning, Guangxi, China, 530021.
Cochrane Database Syst Rev. 2011 Aug 10(8):CD008788. doi: 10.1002/14651858.CD008788.pub2.
Gastrectomy remains the primary therapeutic method for resectable gastric cancer. Thought of as an important measure to reduce post-operative complications and mortality, abdominal drainage was used widely after gastrectomy for gastric cancer in previous decades. The benefits of abdominal drainage have been questioned by researchers in recent years.
The objectives of this review were to access the benefits and harms of routine abdominal drainage post gastrectomy for gastric cancer.
We searched the Cochrane Controlled Trials Register (Central/CCTR) in The Cochrane Library (2010, Issue 10), including the Specialised Registers of the Cochrane Upper Gastrointestinal and Pancreatic Diseases (UGPD) Group; MEDLINE (via Pubmed, 1950 to October, 2010); EMBASE (1980 to October, 2010); and the Chinese National Knowledge Infrastructure (CNKI) Database (1979 to October, 2010).
We included randomised controlled trials (RCTs) comparing abdominal drain versus no drain in patients who had undergone gastrectomy (not considering the scale of gastrectomy and the extent of lymphadenectomy; irrespective of language, publication status, and the type of drain). We excluded RCTs comparing one drain with another.
From each trial, we extracted the data on the methodological quality and characteristics of the included studies, mortality (30-day mortality), re-operations, post-operative complications (pneumonia, wound infection, intra-abdominal abscess, anastomotic leak, drain-related complications), operation time, length of post-operative hospital stay and initiation of soft diet. For dichotomous data, we calculated the risk ratio (RR) and 95% confidence intervals (CI). For continuous data, we calculated mean differences (MD) and 95% CI. We tested heterogeneity using the Chi(2) test. We used a fixed-effect model for data analysis with RevMan software but we used a random-effects model if the P value of the Chi(2) test was less than 0.1.
We included four RCTs involving 438 patients (220 patients in the drain group and 218 in the no-drain group).There was no evidence of a difference between the two groups in mortality (RR 1.73, 95% CI 0.38 to 7.84); re-operations (RR 2.49, 95% CI 0.71 to 8.74); post-operative complications (pneumonia: RR 1.18, 95% CI 0.55 to 2.54; wound infection: RR 1.23, 95% CI 0.47 to 3.23; intra-abdominal abscess: RR 1.27, 95% CI 0.29 to 5.51; anastomotic leak: RR 0.93, 95% CI 0.06 to 14.47); and initiation of soft diet (MD 0.15 day, 95% CI -0.07 to 0.37). However, the addition of a drain prolonged the operation time (MD 9.07 min, 95% CI 2.56 to 15.57) and post-operative hospital stay (MD 0.69 day, 95% CI 0.18 to 1.21) and lead to drain-related complications. Additionally, we should note that 30-day mortality and re-operations are very rare events and, as a result, very large numbers of patients would be required to make any sensible conclusions about whether the two groups were similar. The overall quality of the evidence according to the GRADE approach was "Very Low" for mortality and re-operations, and "Low" for post-operative complications, operation time, and post-operative length of stay.
AUTHORS' CONCLUSIONS: We found no convincing evidence to support routine drain use after gastrectomy for gastric cancer.
胃切除术仍是可切除胃癌的主要治疗方法。在过去几十年里,腹部引流被广泛应用于胃癌胃切除术后,被视为减少术后并发症和死亡率的一项重要措施。近年来,腹部引流的益处受到了研究人员的质疑。
本综述的目的是评估胃癌胃切除术后常规腹部引流的益处和危害。
我们检索了《Cochrane图书馆》(2010年第10期)中的Cochrane对照试验注册库(Central/CCTR),包括Cochrane上消化道和胰腺疾病(UGPD)组的专业注册库;MEDLINE(通过PubMed,1950年至2010年10月);EMBASE(1980年至2010年10月);以及中国国家知识基础设施(CNKI)数据库(1979年至2010年10月)。
我们纳入了比较胃切除术后患者腹部引流与不引流的随机对照试验(RCT)(不考虑胃切除的规模和淋巴结清扫的范围;不考虑语言、发表状态和引流类型)。我们排除了比较一种引流与另一种引流的RCT。
从每项试验中,我们提取了纳入研究的方法学质量和特征、死亡率(30天死亡率)、再次手术、术后并发症(肺炎、伤口感染、腹腔内脓肿、吻合口漏、与引流相关的并发症)、手术时间、术后住院时间和开始软食的数据。对于二分法数据,我们计算风险比(RR)和95%置信区间(CI)。对于连续数据,我们计算平均差(MD)和95%CI。我们使用卡方检验来检验异质性。我们使用RevMan软件进行固定效应模型的数据分析,但如果卡方检验的P值小于0.1,则使用随机效应模型。
我们纳入了4项RCT,涉及438例患者(引流组220例,无引流组218例)。两组在死亡率(RR 1.73,95%CI 0.38至7.84)、再次手术(RR 2.49,95%CI 0.71至8.74)、术后并发症(肺炎:RR 1.18,95%CI 0.55至2.54;伤口感染:RR 1.23,95%CI 0.47至3.23;腹腔内脓肿:RR 1.27,95%CI 0.29至5.51;吻合口漏:RR 0.93,95%CI 0.06至14.47)和开始软食(MD 0.15天,95%CI -0.07至0.37)方面没有差异的证据。然而,放置引流管延长了手术时间(MD 9.07分钟,95%CI 2.56至15.57)和术后住院时间(MD 0.69天,95%CI 0.18至1.21),并导致了与引流相关的并发症。此外,我们应该注意到30天死亡率和再次手术是非常罕见的事件,因此,需要非常大量的患者才能得出关于两组是否相似的任何合理结论。根据GRADE方法,关于死亡率和再次手术的证据总体质量为“极低”,关于术后并发症、手术时间和术后住院时间的证据质量为“低”。
我们没有找到令人信服的证据支持胃癌胃切除术后常规使用引流管。